Dataset

Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)

Plasma cfDNA whole-genome sequencing cohort reanalysed by Hou et al. 2024.

Research readiness

These checks assess whether the evidence supports a reproducible investigation. A source-checked score alone does not meet these requirements.

Release 2026-10-10-7b8f80935f90 · Evidence verified: Not verified

Evidence incomplete

Replay metrics

Exact outcomes, predictions, identifiers and evaluator are connected.

Missing or unresolved evidence

No verified artifact manifest is linked to this exact record.
artifact hashes: verification is missing
join integrity: verification is missing
score semantics: verification is missing
metric replay: verification is missing

Verified: Not verified

Evidence incomplete

Investigate discrepancies

Replay evidence includes annotations and an assessment of dependence. Unknown independence permits descriptive analysis only.

Missing or unresolved evidence

No verified artifact manifest is linked to this exact record.
artifact hashes: verification is missing
join integrity: verification is missing
score semantics: verification is missing
metric replay: verification is missing
annotations: verification is missing
dependence: verification is missing

Verified: Not verified

Evidence incomplete

Run locally

A pinned recipe describes the inputs, environment and resource requirements.

Missing or unresolved evidence

No verified artifact manifest is linked to this exact record.
artifact hashes: verification is missing
join integrity: verification is missing
score semantics: verification is missing
recipe pinned: verification is missing
resource estimate: verification is missing

Verified: Not verified

Evidence incomplete

Validate independently

Separate data and exposure records support an independent test.

Missing or unresolved evidence

No verified artifact manifest is linked to this exact record.
artifact hashes: verification is missing
join integrity: verification is missing
score semantics: verification is missing
independent validation: verification is missing
overlap checked: verification is missing

Verified: Not verified

Readiness describes the evidence in this release. Availability on your computer is checked separately when an investigation runs. Existing data exposure can prevent independent validation even when files are available.

Artifacts and reproduction

No verified artifact manifest is connected to this record yet. The gaps above identify what is needed before analysis can begin.

Read reviewed discrepancy investigations

Evaluation results

10 evaluations · 30 results. Different protocols are not a single leaderboard.

Filter evaluations

Tested model or methodProtocolDatasetEvaluation setupMetricEvidence origin

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configuration	Protocol and dataset	Finding	Evidence and details
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.891 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C12; data set 'Zhou et al. dataset (LIHC)'; row 'EDM'; column 'AUC'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.75 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E12; data set 'Zhou et al. dataset (LIHC)'; row 'EDM'; column 'Sensitivity @85% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.75 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, D12; data set 'Zhou et al. dataset (LIHC)'; row 'EDM'; column 'Sensitivity @95% specificity'
Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.797 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source coverage (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C7; data set 'Zhou et al. dataset (LIHC)'; row 'coverage'; column 'AUC'
Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.625 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source coverage (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E7; data set 'Zhou et al. dataset (LIHC)'; row 'coverage'; column 'Sensitivity @85% specificity'
Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.125 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source coverage (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, D7; data set 'Zhou et al. dataset (LIHC)'; row 'coverage'; column 'Sensitivity @95% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.922 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C8; data set 'Zhou et al. dataset (LIHC)'; row 'end'; column 'AUC'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.875 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E8; data set 'Zhou et al. dataset (LIHC)'; row 'end'; column 'Sensitivity @85% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.5 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, D8; data set 'Zhou et al. dataset (LIHC)'; row 'end'; column 'Sensitivity @95% specificity'
Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.5 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source length (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C3; data set 'Zhou et al. dataset (LIHC)'; row 'length'; column 'AUC'
Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.25 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source length (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E3; data set 'Zhou et al. dataset (LIHC)'; row 'length'; column 'Sensitivity @85% specificity'
Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source length (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, D3; data set 'Zhou et al. dataset (LIHC)'; row 'length'; column 'Sensitivity @95% specificity'
Configuration: Fragment size distribution (FSD), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.563 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source FSD (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C6; data set 'Zhou et al. dataset (LIHC)'; row 'FSD'; column 'AUC'
Configuration: Fragment size distribution (FSD), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.5 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source FSD (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E6; data set 'Zhou et al. dataset (LIHC)'; row 'FSD'; column 'Sensitivity @85% specificity'
Configuration: Fragment size distribution (FSD), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.125 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source FSD (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, D6; data set 'Zhou et al. dataset (LIHC)'; row 'FSD'; column 'Sensitivity @95% specificity'
Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.813 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source FSR (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C5; data set 'Zhou et al. dataset (LIHC)'; row 'FSR'; column 'AUC'
Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.5 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source FSR (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E5; data set 'Zhou et al. dataset (LIHC)'; row 'FSR'; column 'Sensitivity @85% specificity'
Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.375 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source FSR (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, D5; data set 'Zhou et al. dataset (LIHC)'; row 'FSR'; column 'Sensitivity @95% specificity'
Configuration: Integrated fragmentation score (IFS), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.813 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source IFS (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C10; data set 'Zhou et al. dataset (LIHC)'; row 'IFS'; column 'AUC'
Configuration: Integrated fragmentation score (IFS), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.625 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source IFS (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E10; data set 'Zhou et al. dataset (LIHC)'; row 'IFS'; column 'Sensitivity @85% specificity'
Configuration: Integrated fragmentation score (IFS), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.125 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source IFS (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, D10; data set 'Zhou et al. dataset (LIHC)'; row 'IFS'; column 'Sensitivity @95% specificity'
Configuration: Orientation-aware cell-free fragmentation (OCF), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.875 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source OCF (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C9; data set 'Zhou et al. dataset (LIHC)'; row 'OCF'; column 'AUC'
Configuration: Orientation-aware cell-free fragmentation (OCF), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.625 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source OCF (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E9; data set 'Zhou et al. dataset (LIHC)'; row 'OCF'; column 'Sensitivity @85% specificity'
Configuration: Orientation-aware cell-free fragmentation (OCF), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.625 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source OCF (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, D9; data set 'Zhou et al. dataset (LIHC)'; row 'OCF'; column 'Sensitivity @95% specificity'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.766 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source PFE (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C4; data set 'Zhou et al. dataset (LIHC)'; row 'PFE'; column 'AUC'

Source checking is not independent reproduction. Release 2026-10-10-7b8f80935f90.

Dataset and evaluation context

A dataset supplies biological observations. The evaluation protocol defines how those observations are split, used and scored.

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

8 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-10-10-7b8f80935f90
Property and statement	Original source and location	Review and provenance
attributes.assay Plasma cfDNA whole-genome sequencing Context-only references	Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns Original source ↗ Hou et al. 2024 Experimental Section 'Cell-Free DNA Whole Genome Sequencing Data and Preprocessing' (P24-P25) Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML Retrieved: 2026-10-09T20:27:02Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.assay` Source artifact SHA-256: `d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
attributes.population 16 samples: 8 healthy and 8 liver cancer; fragment information from the original paper Context-only references	Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns Original source ↗ Hou et al. 2024 Experimental Section 'Cell-Free DNA Whole Genome Sequencing Data and Preprocessing' (P24-P25) Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML Retrieved: 2026-10-09T20:27:02Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.population` Source artifact SHA-256: `d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
attributes.scope_note Published in Zhou et al. 2022 (Genome Medicine 14:138, Hou et al. ref 10), the CRAG paper that defines IFS. Its first author, Xionghui Zhou, is Hou et al.'s corresponding author. Context-only references	Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns Original source ↗ Hou et al. 2024 Experimental Section 'Cell-Free DNA Whole Genome Sequencing Data and Preprocessing' (P24-P25) Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML Retrieved: 2026-10-09T20:27:02Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.scope_note` Source artifact SHA-256: `d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
attributes.source_locator Hou et al. 2024 Experimental Section 'Cell-Free DNA Whole Genome Sequencing Data and Preprocessing' (P24-P25) Context-only references	Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns Original source ↗ Hou et al. 2024 Experimental Section 'Cell-Free DNA Whole Genome Sequencing Data and Preprocessing' (P24-P25) Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML Retrieved: 2026-10-09T20:27:02Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.source_locator` Source artifact SHA-256: `d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
attributes.total 16 Context-only references	Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns Original source ↗ Hou et al. 2024 Experimental Section 'Cell-Free DNA Whole Genome Sequencing Data and Preprocessing' (P24-P25) Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML Retrieved: 2026-10-09T20:27:02Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.total` Source artifact SHA-256: `d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
attributes.version As reanalysed by Hou et al. 2024 (GRCh37) Context-only references	Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns Original source ↗ Hou et al. 2024 Experimental Section 'Cell-Free DNA Whole Genome Sequencing Data and Preprocessing' (P24-P25) Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML Retrieved: 2026-10-09T20:27:02Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.version` Source artifact SHA-256: `d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
description Plasma cfDNA whole-genome sequencing cohort reanalysed by Hou et al. 2024. Context-only references	Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns Original source ↗ Hou et al. 2024 Experimental Section 'Cell-Free DNA Whole Genome Sequencing Data and Preprocessing' (P24-P25) Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML Retrieved: 2026-10-09T20:27:02Z	not individually reviewed No individual claim review recorded Audit details Field: `description` Source artifact SHA-256: `d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
name Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024) Context-only references	Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns Original source ↗ Hou et al. 2024 Experimental Section 'Cell-Free DNA Whole Genome Sequencing Data and Preprocessing' (P24-P25) Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML Retrieved: 2026-10-09T20:27:02Z	not individually reviewed No individual claim review recorded Audit details Field: `name` Source artifact SHA-256: `d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact

All evidence (JSONL) (gzip)How to read the evidence

Sources and history

Release 2026-10-10-7b8f80935f90 · Record review: source checked

1 source records and release history

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns · Original source · Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML

Download this release (gzip)

Technical metadata and extraction receipts

Stable ID: ctdnafrag-20261009-data-hou2024-zhou2022-lihc

areas: dna-genomes
contexts: clinical_research
version: As reanalysed by Hou et al. 2024 (GRCh37)
population: 16 samples: 8 healthy and 8 liver cancer; fragment information from the original paper
total: 16
assay: Plasma cfDNA whole-genome sequencing
source locator: Hou et al. 2024 Experimental Section 'Cell-Free DNA Whole Genome Sequencing Data and Preprocessing' (P24-P25)
scope note: Published in Zhou et al. 2022 (Genome Medicine 14:138, Hou et al. ref 10), the CRAG paper that defines IFS. Its first author, Xionghui Zhou, is Hou et al.'s corresponding author.

Related records

Suggest a correction